国际口腔医学杂志 ›› 2018, Vol. 45 ›› Issue (2): 155-161.doi: 10.7518/gjkq.2018.02.007

• 口腔黏膜专栏 • 上一篇    下一篇

天疱疮的免疫抑制剂治疗方法

姚懿桓, 王冏珂, 赵奎, 时玉洁, 曾昕, 陈谦明   

  1. 口腔疾病研究国家重点实验室 国家口腔疾病临床医学研究中心
    四川大学华西口腔医院口腔黏膜病科 成都 610041
  • 收稿日期:2017-07-31 修回日期:2017-12-04 出版日期:2018-03-01 发布日期:2018-03-01
  • 通讯作者: 曾昕,教授,博士,Email:zengxin22@163.com
  • 作者简介:姚懿桓,硕士,Email:525218951@qq.com
  • 基金资助:
    国家自然科学基金(81472533); 国家卫生和计划生育委员会公益性行业专项(201502018)

Immunosuppressive adjuvant therapy for pemphigus

Yao Yihuan, Wang Jiongke, Zhao Kui, Shi Yujie, Zeng Xin, Chen Qianming   

  1. State Key Laboratory of Oral Diseases &National Clinical Research Center for Oral Diseases &Dept. of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2017-07-31 Revised:2017-12-04 Online:2018-03-01 Published:2018-03-01
  • Supported by:
    This study was supported by National Natural Science Foundation of China (81472533) and Nonprofit Industry Research Sepecific Fund of National Health and Family Planning Commission of China (201502018).

摘要: 天疱疮是一种累及皮肤及黏膜的严重的慢性自身免疫大疱性疾病。目前,糖皮质激素作为治疗天疱疮的首选药物,在控制病情的同时也可能引起各种并发症。为减轻激素治疗的不良反应,常需与免疫抑制剂类药物联合运用或采用其他疗法。因此,笔者就天疱疮的免疫抑制剂疗法作一综述。

关键词: 天疱疮, 免疫抑制剂, 治疗

Abstract: Pemphigus is a severe, chronic, autoimmune bullous disease that affects the skin and mucous membranes. To date, glucocorticoidis the first treatment medicine for pemphigus. Nevertheless, the use of glucocorticoid may result in adverse effects during treatment of this disease. Therefore, several immunosuppressive adjuvant therapies or non-medicinal therapies should be adopted to relieve the side effects of glucocorticoid. Thus, we reviewed the immunosuppressive therapy in this article.

Key words: pemphigus, immunosuppressants, therapy

中图分类号: 

  • R781.5+9
[1] Bystryn JC.Adjuvant therapy of pemphigus[J]. Arch Dermatol, 1984, 120(7):941-951.
[2] 江潞, 陈谦明. 天疱疮的糖皮质激素治疗[J]. 国外医学口腔医学分册, 2004, 31(6):478-480.
Jiang L, Chen QM.The glucocorticoid therapy of pemphigus[J]. Foreign Med Sci: Stomatol, 2004, 31(6):478-480.
[3] Rosenberg FR, Sanders S, Nelson CT.Pemphigus: a 20-year review of 107 patients treated with cortico-steroids[J]. Arch Dermatol, 1976, 112(7):962-970.
[4] Schiavo AL, Puca RV, Ruocco V, et al.Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: facts and controversies[J]. Clin Dermatol, 2010, 28(3):337-343.
[5] Meurer M.Immunosuppressive therapy for autoim-mune bullous diseases[J]. Clin Dermatol, 2012, 30(1):78-83.
[6] Sandborn WJ.State-of-the-art: immunosuppression and biologic therapy[J]. Dig Dis, 2010, 28(3):536-542.
[7] Anstey AV, Wakelin S, Reynolds NJ, et al.Guidelines for prescribing azathioprine in dermatology[J]. Br J Dermatol, 2004, 151(6):1123-1132.
[8] Weinshilboum RM, Sladek SL.Mercaptopurine phar-macogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity[J]. Am J Hum Genet, 1980, 32(5):651-662.
[9] Hertl M, Jedlickova H, Karpati S, et al.Pemphigus. S2 guideline for diagnosis and treatment—guided by the European Dermatology Forum (EDF) in co-operation with the European Academy of Dermato-logy and Venereology (EADV)[J]. J Eur Acad Der-matol Venereol, 2015, 29(3):405-414.
[10] Committee for Guidelines for the Management of Pemphigus Disease, Amagai M, Tanikawa A, et al. Japanese guidelines for the management of pemphi-gus[J]. J Dermatol, 2014, 41(6):471-486.
[11] Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al.Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris[J]. J Am Acad Dermatol, 2007, 57(4):622-628.
[12] Esmaili N, Chams-Davatchi C, Valikhani M, et al.Assessment of the therapeutic benefit of oral predni-solone and common adjuvant therapy in stage Ⅱ of randomized controlled trial study for management of pemphigus vulgaris[J]. Arch Iran Med, 2014, 17(9): 626-628.
[13] Chams-Davatchi C, Mortazavizadeh A, Daneshpa-zhooh M, et al. Randomized double blind trial of pre-dnisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris[J]. J Eur Acad Dermatol Venereol, 2013, 27(10):1285-1292.
[14] Aberer W, Wolff-Schreiner EC, Stingl G, et al.Aza-thioprine in the treatment of pemphigus vulgaris. A long-term follow-up[J]. J Am Acad Dermatol, 1987, 16(3 Pt 1):527-533.
[15] Younger IR, Harris DW, Colver GB.Azathioprine in dermatology[J]. J Am Acad Dermatol, 1991,25(2 Pt 1):281-286.
[16] Doukaki S, Pistone G, Aricò M, et al.Pharmacoki-netic evaluation of mycophenolate mofetil for pem-phigus[J]. Expert Opin Drug Metab Toxicol, 2011, 7(2):237-244.
[17] Doukaki S, Platamone A, Alaimo R, et al.Mycophe-nolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus[J]. J Dermatolog Treat, 2015, 26(1):67-72.
[18] Beissert S, Werfel T, Frieling U, et al.A comparison of oral methylprednisolone plus azathioprine or myco-phenolate mofetil for the treatment of pemphigus[J]. Arch Dermatol, 2006, 142(11):1447-1454.
[19] Beissert S, Mimouni D, Kanwar AJ, et al.Treating pemphigus vulgaris with prednisone and mycophe-nolate mofetil: a multicenter, randomized, placebo-controlled trial[J]. J Invest Dermatol, 2010, 130(8): 2041-2048.
[20] Ioannides D, Apalla Z, Lazaridou E, et al.Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study[J]. J Eur Acad Dermatol Venereol, 2012, 26(7):855-860.
[21] Fleming RA.An overview of cyclophosphamide and ifosfamide pharmacology[J]. Pharmacotherapy, 1997, 17(5 Pt 2):146S-154S.
[22] Sharma VK, Khandpur S.Evaluation of cyclophos-phamide pulse therapy as an adjuvant to oral cortico-steroid in the management of pemphigus vulgaris[J]. Clin Exp Dermatol, 2013, 38(6):659-664.
[23] Rose E, Wever S, Zilliken D, et al.Intravenous dexa-methasone-cyclophosphamide pulse therapy in com-parison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a mul-ticenter prospectively randomized study[J]. J Dtsch Dermatol Ges, 2005, 3(3):200-206.
[24] Sethy PK, Khandpur S, Sharma VK.Randomized open comparative trial of dexamethasone-cyclopho-sphamide pulse and daily oral cyclophosphamide versus cyclophosphamide pulse and daily oral pred-nisolone in pemphigus vulgaris[J]. Indian J Dermatol Venereol Leprol, 2009, 75(5):476-482.
[25] Talar-Williams C, Hijazi YM, Walther MM, et al.Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis[J]. Ann Intern Med, 1996, 124(5):477-484.
[26] Cummins DL, Mimouni D, Anhalt GJ, et al.Oral cyc-lophosphamide for treatment of pemphigus vulgaris and foliaceus[J]. J Am Acad Dermatol, 2003, 49(2): 276-280.
[27] Damiano S, Ciarcia R, Montagnaro S, et al.Prevention of nephrotoxicity induced by cyclosporine-A: role of antioxidants[J]. J Cell Biochem, 2015, 116(3):364-369.
[28] Lapidoth M, David M, Ben-Amitai D, et al.The effi-cacy of combined treatment with prednisone and cyc-losporine in patients with pemphigus: preliminary study[J]. J Am Acad Dermatol, 1994, 30(5 Pt 1):752-757.
[29] Mobini N, Padilla T Jr, Ahmed AR.Long-term re-mission in selected patients with pemphigus vulgaris treated with cyclosporine[J]. J Am Acad Dermatol, 1997, 36(2 Pt 1):264-266.
[30] Ioannides D, Chrysomallis F, Bystryn JC.Ineffec-tiveness of cyclosporine as an adjuvant to cortico-steroids in the treatment of pemphigus[J]. Arch Der-matol, 2000, 136(7):868-872.
[31] Genestier L, Paillot R, Quemeneur L, et al.Mecha-nisms of action of methotrexate[J]. Immunopharma-cology, 2000, 47(2/3):247-257.
[32] Gürcan HM, Ahmed AR.Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid[J]. Br J Dermatol, 2009, 161(4): 723-731.
[33] Tran KD, Wolverton JE, Soter NA.Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients[J]. Br J Dermatol, 2013, 169(4):916-921.
[34] Harman KE, Albert S, Black MM, et al.Guidelines for the management of pemphigus vulgaris[J]. Br J Dermatol, 2003, 149(5):926-937.
[35] Cronstein BN.Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis[J]. Pharmacol Rev, 2005, 57(2):163-172.
[36] Shah N, Green AR, Elgart GW, et al.The use of chlo-rambucil with prednisone in the treatment of pem-phigus[J]. J Am Acad Dermatol, 2000, 42(1 Pt 1): 85-88.
[37] Sugita K, Hirokawa H, Izu K, et al.D-penicillamine-induced pemphigus successfully treated with combi-nation therapy of mizoribine and prednisolone[J]. J Dermatolog Treat, 2004, 15(4):214-217.
[38] Turka LA, Dayton J, Sinclair G, et al.Guanine ribo-nucleotide depletion inhibits T cell activation. Me-chanism of action of the immunosuppressive drug mizoribine[J]. J Clin Invest, 1991, 87(3):940-948.
[39] Dastgheib L, Sadati MS, Baghernejhad M.Assess-ment of the adjuvant effect of tacrolimus in the ma-nagement of pemphigus vulgaris: a randomized con-trolled trial[J]. J Dermatolog Treat, 2015, 26(1):90-93.
[40] Büsing V, Kern JS, Bruckner-Tuderman L, et al.Re-calcitrant pemphigus vulgaris responding to systemic tacrolimus[J]. Dermatology, 2010, 221(2):122-126.
[41] Cohen SN, Lim RP, Paul CJ, et al.Equal efficacy of topical tacrolimus and clobetasone butyrate in pem-phigus foliaceus[J]. Int J Dermatol, 2006, 45(11): 1379.
[1] 李继遥,郑广宁. 原发性牙根纵裂的诊治策略[J]. 国际口腔医学杂志, 2020, 47(4): 373-382.
[2] 张琳琳,杜毅. 畸形舌侧沟的治疗进展[J]. 国际口腔医学杂志, 2020, 47(4): 458-462.
[3] 张敏,万浩元. 种植体周围炎药物治疗与激光治疗的研究进展[J]. 国际口腔医学杂志, 2020, 47(4): 463-470.
[4] 吴秋月,李治邦. 药物辅助治疗种植体周围炎的研究进展[J]. 国际口腔医学杂志, 2020, 47(4): 471-477.
[5] 赵玉洁,管晓燕,李小兰,陈琦君,王倩,刘建国. 巨噬细胞极化参与正畸牙移动的研究进展[J]. 国际口腔医学杂志, 2020, 47(4): 478-483.
[6] 唐蓓,赵文俊,王虎,郑广宁,游梦. 根管超填导致下牙槽神经损伤2例[J]. 国际口腔医学杂志, 2020, 47(3): 293-296.
[7] 吴勇志,尧可,陈思宇,黄能文,王了. 多生牙及其诊断治疗[J]. 国际口腔医学杂志, 2020, 47(3): 311-317.
[8] 陈艺尹,刘俊圻,李承浩. 牙槽突裂的裂隙特点及正畸治疗对唇腭裂患者牙槽突植骨术的影响[J]. 国际口腔医学杂志, 2020, 47(3): 345-350.
[9] 于林彤,宋光泰. 铒激光在儿童口腔医学中的应用[J]. 国际口腔医学杂志, 2020, 47(3): 351-355.
[10] 田国莉,江潞,陈谦明,曾昕. 味觉异常的病因和治疗研究进展[J]. 国际口腔医学杂志, 2020, 47(3): 356-361.
[11] 陈斌,徐蓉蓉,张家鼎,闫福华. 重度牙周炎患牙的保存治疗[J]. 国际口腔医学杂志, 2020, 47(2): 125-130.
[12] 蔡潇潇. 美学区数字化种植策略与流程[J]. 国际口腔医学杂志, 2019, 46(6): 621-630.
[13] 陈东,杨征,蒋丽. 放射性口腔干燥症的评估与临床管理的研究进展[J]. 国际口腔医学杂志, 2019, 46(6): 711-717.
[14] 宋少华,莫水学. 唇腭裂患者序列治疗中的正畸治疗[J]. 国际口腔医学杂志, 2019, 46(6): 740-744.
[15] 许庆安,樊明文. 非器械根管治疗与多声波超洁净系统[J]. 国际口腔医学杂志, 2019, 46(5): 522-525.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 王昆润. 在种植体上制作固定义齿以后下颌骨密度的动态变化[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 温秀杰. 氟化物对牙本质脱矿抑制作用的体外实验研究[J]. 国际口腔医学杂志, 1999, 26(05): .
[3] 杨儒壮 孙宏晨 欧阳喈. 纳米级高分子支架材料在组织工程中的研究进展[J]. 国际口腔医学杂志, 2004, 31(02): 126 -128 .
[4] 李中杰 谢翠柳综述 孟玉坤审校. 贴面修复临床效果的相关因素研究[J]. 国际口腔医学杂志, 2013, 40(4): 489 -492 .
[5] 黄丽娟,李建,. 髁突位置与颞下颌关节盘移位关系的研究[J]. 国际口腔医学杂志, 2007, 34(02): 104 -106 .
[6] 薛明,葛久禹,程磊. 根管冲洗液对电子根测仪准确性的影响[J]. 国际口腔医学杂志, 2016, 43(1): 5 .
[7] 蒋贤军 胡德渝 肖强 涂蕊 董滢. 成都市部分6~12岁孤残儿童患龋状况及防治探讨[J]. 国际口腔医学杂志, 2013, 40(2): 152 -155 .
[8] 王昆润. 口腔印模表面用次氯酸钠溶液消毒的实验研究[J]. 国际口腔医学杂志, 1999, 26(02): .
[9] 张凤,魏素华. 嵌体适合性分析的实验方法[J]. 国际口腔医学杂志, 2008, 35(S1): .
[10] 吴园 刘传霞综述 李晓英审校. 复发性阿弗他溃疡与饮食调理[J]. 国际口腔医学杂志, 2012, 39(6): 808 -810 .